AR069636A1 - Triazolo triazinas y triazolopirazinas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y uso de las mismas para el tratamiento y/o profilaxis de trastornos hematologicos,tales como neutropenias y leucopenias. - Google Patents

Triazolo triazinas y triazolopirazinas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y uso de las mismas para el tratamiento y/o profilaxis de trastornos hematologicos,tales como neutropenias y leucopenias.

Info

Publication number
AR069636A1
AR069636A1 ARP080105333A ARP080105333A AR069636A1 AR 069636 A1 AR069636 A1 AR 069636A1 AR P080105333 A ARP080105333 A AR P080105333A AR P080105333 A ARP080105333 A AR P080105333A AR 069636 A1 AR069636 A1 AR 069636A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
aminocarbonyl
carbonyl
Prior art date
Application number
ARP080105333A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007060172A external-priority patent/DE102007060172A1/de
Priority claimed from DE200810035209 external-priority patent/DE102008035209A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR069636A1 publication Critical patent/AR069636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)

Abstract

Reivindicacion 1: Compuesto de la formula (1) en la que u representa N, V representa CR12, w representa N, A representa CR15; o u representa N, v representa N, w representa CR16, A representa N, donde R12 representa hidrogeno, hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, trifluorometilo, trifluorometoxi, ciano, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino, alquil C1-4-sulfonilamino, heterociclilcarbonilo de 5 o 6 miembros, -CH2R13 o -CH2CH2R14, donde heterociclilcarbonilo está sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde alcoxi, alquilamino, alquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo, alquilcarbonilamino y alquilsulfonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, alquil C1-4-carbonilamino, heterociclilo de 5 o 6 miembros y fenilo, donde fenilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde R13 representa hidroxilo, amino, ciano, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino o heterociclilo de 5 o 6 miembros, donde alcoxi, alquilamino, alcoxicarbonilo, alquilaminocarbonilo y alquilcarbonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde R14 representa hidroxilo, amino, ciano, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino o heterociclilo de 5 o 6 miembros, donde alcoxi, alquilamino, alcoxicarbonilo, alquilaminocarbonilo y alquilcarbonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 2 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, R15 representa hidrogeno, halogeno, ciano, trifluorometilo, alquilo C1-3, metoxi, metiltio o ciclopropilo, R16 representa hidrogeno o metilo; representa un resto del grupo de formulas (2) en las que * es el punto de union al heterociclo, n representa el numero 0 o 1; X representa NR10, S u O, donde R10 representa hidrogeno, alquilo C1-3 o ciclopropilo, Y representa NR11 o S, donde R11 representa hidrogeno, alquilo C1-3 o ciclopropilo, R3 representa pirid-2-ilo, pirimid-2-ilo, 2-aminopirimid-4-ilo, 2-(mono-(alquil C1-4)-amino)pirimid-4-ilo, 2-(mono-cicloalquilamino C3-4)pirimid-4-ilo, piridazin-3(2H)-on-6-ilo; 1,3-oxazol-2-ilo, 1,3-oxazol-4-ilo, 1,2,4-oxadiazol-3-ilo, 1,2,3-oxadiazol-4-ilo, 1,3-tiazol-2-ilo, 1,3-tiazol-4-ilo, 1H-1,2,4-triazol-5-ilo, 2,4-dihidro-3H-1,2,4-triazol-3-on-5-ilo o 1,2-pirazol-5-ilo, donde pirid-2-ilo, pirimid-2-ilo, 1,3-oxazol-2-ilo, 1,3-oxazol-4-ilo, 1,3-tiazol-2-ilo y 1,3-tiazol-4-ilo están sustituidos con 1 o 2 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, nitro, amino, trifluorometilo, trifluorometoxi, aminocarbonilo, trifluorometilcarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, cicloalquilamino C3-4, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y ciclo alquilcarbonilo C3-6, donde alquilo, alcoxi, alquilamino, alquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo y cicloalquilcarbonilo pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por halogeno, ciano, hidroxilo, amino, trifluorometilo y cicloalquilo C3-5, y donde 2-aminopirimid-4-ilo, 2-(mono-(alquil C1-4)-amino)pirimid-4-ilo, 2-(mono-C3-4-cicloalquilamino)pirinlid-4-ilo, piridazin-3(2H)-on-6-ilo, 1,2,4-oxadiazol-3-ilo, 1,2,3-oxadiazol-4-ilo, 1H-1,2,4-triazol-5-ilo, 2,4-dihidro-3H-1,2,4-triazol-3-on-5-ilo y 1,2-pirazol-5-ilo pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por halogeno, ciano, nitro, amino, trifluorometilo, trifluorometoxi, aminocarbonilo, trifluorometilcarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, cicloalquilamino C3-4, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y cicloalquilcarbonilo C3-6, R4 representa hidrogeno, alquilo C1-3 o ciclopropilo, R5 representa hidrogeno o alquilo C1-3, R6 representa hidrogeno, alquilo C1-3 o ciclopropilo, R7 representa hidrogeno o alquilo C1-3, R8 representa hidrogeno, alquilo C1-3 o ciclopropilo, R9 representa hidrogeno o alquilo C1-3, R2 representa arilo C5-10 o heteroarilo de 5 a 10 miembros, donde arilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por hidroxilo, hidroximetilo, amino, halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alcoxi C1-4)metilo, (alquil C1-4)amino, (alquil C1-4)-aminometilo, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino, (alquil C1-4)sulfonilo, (alquil C1-4)sulfonilamino, (alquil C1-4)-aminosulfonilo, fenilo, benciloxi, heterociclilo de 5 o 6 miembros, heterociclilcarbonilo de 5 o 6 miembros, heterociclilmetilo de 5 o 6 miembros y heteroarilo de 5 o 6 miembros, donde fenilo, benciloxi, heterociclilo, heterociclilcarbonilo, heterociclilmetilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, o dos de los sustituyentes en arilo junto con los átomos de carbono a los que están unidos forman un 1,3-dioxolano o 1,4-dioxano; o una de sus sales, sus solvatos o los solvatos de sus sales.
ARP080105333A 2007-12-13 2008-12-09 Triazolo triazinas y triazolopirazinas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y uso de las mismas para el tratamiento y/o profilaxis de trastornos hematologicos,tales como neutropenias y leucopenias. AR069636A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007060172A DE102007060172A1 (de) 2007-12-13 2007-12-13 Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE200810035209 DE102008035209A1 (de) 2008-07-29 2008-07-29 Triazolotriazine und Triazolopyrazine und ihre Verwendung

Publications (1)

Publication Number Publication Date
AR069636A1 true AR069636A1 (es) 2010-02-10

Family

ID=40578190

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105333A AR069636A1 (es) 2007-12-13 2008-12-09 Triazolo triazinas y triazolopirazinas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y uso de las mismas para el tratamiento y/o profilaxis de trastornos hematologicos,tales como neutropenias y leucopenias.

Country Status (11)

Country Link
US (1) US20090258877A1 (es)
EP (1) EP2229392A1 (es)
JP (1) JP2011506364A (es)
AR (1) AR069636A1 (es)
CA (1) CA2708783A1 (es)
CL (1) CL2008003602A1 (es)
PA (1) PA8806501A1 (es)
PE (1) PE20091074A1 (es)
TW (1) TW200938546A (es)
UY (1) UY31508A1 (es)
WO (1) WO2009074259A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0206464A (pt) 2001-01-16 2005-01-18 Vascular Therapies Llc Aparelho e processos para impedir ou tratar insuficiência de acesso vascular para hemodiálise e outros enxertos vasculares
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
TW202402759A (zh) 2018-07-05 2024-01-16 美商英塞特公司 作為a2a/a2b抑制劑之稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1474147B1 (en) * 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Pyrimidine-based compounds useful as gsk-3 inhibitors
PE20050081A1 (es) * 2002-09-23 2005-03-01 Schering Corp Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
EP1678180B1 (en) * 2003-10-10 2007-08-08 Pfizer Products Incorporated Substituted 2h-[1,2,4]triazolo 4,3-a pyrazines as gsk-3 inhibitors
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors

Also Published As

Publication number Publication date
EP2229392A1 (de) 2010-09-22
PE20091074A1 (es) 2009-07-26
PA8806501A1 (es) 2009-08-26
TW200938546A (en) 2009-09-16
JP2011506364A (ja) 2011-03-03
CA2708783A1 (en) 2009-06-18
US20090258877A1 (en) 2009-10-15
UY31508A1 (es) 2009-08-03
CL2008003602A1 (es) 2009-10-09
WO2009074259A1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
AR069636A1 (es) Triazolo triazinas y triazolopirazinas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y uso de las mismas para el tratamiento y/o profilaxis de trastornos hematologicos,tales como neutropenias y leucopenias.
AR050364A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
AR065719A1 (es) Imidazo y triazolopirimidinas, un procedimiento para su preparacion y su uso en la elaboracion de un medicamento para el tratamiento de trastornos hematologicos.
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR045747A1 (es) Derivados de 2,4 di (hetero)-arilamino-pirimidina como zap-70 inhibidores
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
PE20230820A1 (es) Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead
AR069417A1 (es) Piperidinas heteroaril - sustituidas
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR076908A1 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
RU2009118602A (ru) Производное индола
AR067327A1 (es) Derivados de piperidina / piperazina
CO6300864A2 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
CO5640135A2 (es) Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer
CO6251263A2 (es) Derivados de bencimidazol e indol sustutuidos por oxadiazol y oxazol como inhibidores de dgat1
AR075868A1 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
AR082888A1 (es) Compuestos de piridina para la inhibicion de nampt
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
AR059493A1 (es) Compuestos inhibidores de erk

Legal Events

Date Code Title Description
FB Suspension of granting procedure